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1. Introduction 
Greater than 200,000 new cases of breast cancer cases were diagnosed in 2010 in the United 
States, with approximately 40,000 women succumbing to the disease (www.cancer.gov). 
Globally, an estimated 1.38 million new cases of breast cancer were diagnosed in 2008, with 
greater than 450,000 women succumbing to the disease (Jemal et al., 2011). Despite our 
improved understanding of breast carcinogenesis, breast cancer remains the second most 
commonly diagnosed cancer in women behind non-melanoma skin cancer and the second 
leading cause of death in women behind lung cancer. These epidemiological statistics 
highlight the overwhelming clinical dilemma of breast cancer and emphasize the need for 
novel therapeutic targets and prevention strategies. Countless studies in the fields of 
mammary gland development and breast cancer have led to an appreciation of a breast 
tumor microenvironment that actively contributes to the heterogeneous nature of breast 
cancer. The current review will focus on the impact of IL-6 and STAT3 activation in the 
breast tumor microenvironment and subsequently present rationale for targeting the IL-
6/STAT3 signaling pathway in this setting. IL-6 is a quintessential pleiotropic cytokine 
produced by a diverse number of cell populations, most of which can localize to the breast 
tumor microenvironment. Excessive IL-6 has been demonstrated in primary breast tumors 
and breast cancer patient sera and is associated with poor clinical outcomes in breast cancer. 
These clinical associations are corroborated by emerging preclinical data revealing that IL-6 
is a potent growth factor and promotes an epithelial-mesenchymal (EMT) phenotype in 
breast cancer cells to indicate that IL-6 in the breast tumor microenvironment is clinically 
relevant. Numerous clinical reports have now demonstrated the safety and efficacy of IL-6 
signaling antagonists in multiple diseases, which supports future investigations of these 
therapies in breast cancer. 
Estrogen receptor-alpha (ERǂ) is a latent cytoplasmic ligand-activated transcription factor 
utilized by clinicians to subclassify the heterogeneous disease of breast cancer. ERǂ-positive 
breast cancer incidence increases up to age 51, the mean age of menopause, and continues to 
increase until age 80. Conversely, ERǂ-negative breast cancer incidence plateaus and even 
slightly decreases at age 51, while demonstrating an increase prior to age 50 comparable to 
that of ERǂ-positive disease. This discrepancy between the two incidence rates at 
menopause produces an inflection in the incidence rate of all breast cancer cases which has 
been termed Clemmesen’s hook (Anderson and Matsuno, 2006). Whereas the prevalence of 
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ERǂ-positive cells within terminal duct lobular units of the breast of healthy premenopausal 
women has been reported at 7%, this number is estimated at 42% in postmenopausal 
women (Shoker et al., 1999). In addition, approximately two-thirds of all breast cancers are 
diagnosed as ERǂ-positive, and 75% of postmenopausal breast cancers are ERǂ-positive 
(Macedo et al., 2009). Progesterone receptor (PR) and epidermal growth factor receptor 2 
(EGFR2; HER2; or ErbB2), a receptor tyrosine kinase involved in cellular proliferation, have 
also acquired much clinical attention following reports of dismal survival rates in “triple 
negative” (ERǂ-negative/PR-negative/HER2 not overexpressed) breast cancer patients. 
Triple negative breast cancer represents approximately 15 to 20% of all breast cancer cases 
and can only be treated with standard chemotherapy as it lacks current adjuvant therapeutic 
targets. Such breast tumors are highly proliferative with a high mitotic index, increased 
necrosis, elevated apoptosis, and typically are of higher tumor grade. TP53 gene and p53 
protein mutations as well as loss of the Rb tumor suppressor protein are common. Familial 
breast cancer patients with congenital BRCA1 mutations often present with triple negative 
breast cancer, as do relatively younger breast cancer patients and African American women. 
Currently, triple negative breast cancers are associated with a poor prognosis largely due to 
poor survival rates and early relapse. The fact that these breast tumors respond well if not 
completely to initial chemotherapy may seem counterintuitive, but enhanced invasiveness, 
consequent distant metastasis, and residual local recurrence eventually promote poor 
survival rates (Irvin and Carey, 2008). 
Breast cancer most commonly metastasizes to bone, followed by lung, liver, and brain. 
Perhaps due to the heterogeneity across individual breast cancer cases, few prognostic 
molecular biomarkers have been demonstrated to accurately predict metastatic potential. 
One of the most important of these biomarkers is ERǂ, which is clinically exploited as a 
predictor of bone metastasis (Kominsky and Davidson, 2006). Whereas ERǂ-positive breast 
cancers have a strong tendency to metastasize to bone if at all (James et al., 2003), their ERǂ-
negative counterparts favor visceral organs such as lung and liver (Hess et al., 2003). 
Primary mammary tumor cell dissemination has been quantified at 3 to 4 x 106 primary 
tumor cells in circulation per 24 hours per gram of tumor in a rat mammary carcinoma 
model, which exemplifies the inefficient nature of metastasis (Butler and Gullino, 1975). 
Although metastasis has been generally accepted as a relatively late event throughout 
cancer progression, recent work has revealed evidence of early primary tumor cell 
dissemination, thus refuting this paradigm (Klein, 2009). In particular, it has now been 
demonstrated that untransformed triple transgenic (doxycycline-inducible K-ras, MYC, and 
polyoma middle T antigen) mammary epithelial cells are capable of lung colonization when 
tail vein-injected into immunocompromised female mice on doxycycline. This work showed 
that untransformed “normal” mammary epithelial cells can colonize ectopic lung tissue, and 
upon oncogene activation, disseminated mammary epithelial cells within circulation or a 
foreign host microenvironment are capable of forming tumors at the ectopic site 
(Podsypanina et al., 2008). Additionally, reports of bone marrow cytokeratin-positive 
epithelial cells in up to 48% of breast cancer patients without overt metastases also offer 
support for early primary tumor cell dissemination. Decreased survival in patients with 
such cells was demonstrated in all studies (Braun et al., 2000; Diel et al., 1996; Gebauer et al., 
2001; Pantel et al., 2003; Vannucchi et al., 1998). Furthermore, only 8% of these patients with 
bone marrow micrometastases exhibited cytokeratin-positive/Ki67-positive cells, 
suggesting that lack of overt bone metastasis may be due to disseminated tumor cell 
dormancy (Pantel et al., 2003). 
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2. The breast tumor microenvironment 
A normal epithelial tissue can undergo hyperplasia and acquire tumorigenic properties that 
promote the development of a benign, non-invasive solid tumor known as carcinoma in situ. 
Normal epithelial tissues and non-invasive carcinoma in situ tumors are separated from a 
supportive stromal compartment by an intact basement membrane. Ultimately, carcinoma in 
situ can progress to a malignant, invasive carcinoma, the most common form of human 
cancer. The panoply of published investigations between the fields of mammary gland 
development and breast cancer has led to an appreciation for a supportive non-epithelial 
mammary stroma that mechanically and biologically restrains tumorigenesis. However, 
tumors of the breast and other epithelial tissues obviously overcome these growth restraints 
and exploit this stroma to sculpt a vastly divergent tumor stroma. Tumor stroma is 
generally divided into four main components:  tumor vasculature, inflammatory leukocytes, 
extracellular matrix (ECM) and soluble growth factors, and fibroblasts. Malignant carcinoma 
cells and tumor stromal cells bi-directionally communicate with one another through 
paracrine signaling and intercellular contacts in a disorganized ECM to constitute a tumor 
microenvironment. Tumor-associated fibroblasts (TAF), the predominant stromal cell 
population within the tumor microenvironment, acquire and sustain an “activated” 
phenotype that promotes tumor progression (Rasanen and Vaheri, 2010). TAF are capable of 
enhancing breast tumor growth and metastasis by means of promoting angiogenesis (Orimo 
et al., 2005), epithelial-mesenchymal transition (EMT) (Martin et al., 2010; Radisky et al., 
2005), and progressive genetic instability (Kurose et al., 2001; Moinfar et al., 2000). In 
contrast, a normal mammary microenvironment can act in a dominant manner to inhibit 
tumor growth and “revert” the malignant phenotype of breast cancer cells (Kenny and 
Bissell, 2003). While resident breast tissue fibroblasts can inhabit breast tumors as TAF, 
breast tumors also recruit distant cell populations that engraft within the breast tumor 
microenvironment where they actively contribute as TAF. For example, mesenchymal stem 
cells (MSC), a bone marrow-derived stromal cell population, home to breast cancer cell 
xenograft tumors and persist as TAF (Spaeth et al., 2009). 
3. Cancer-associated inflammation 
Although highly characterized for their protective capacity against infection, inflammatory 
leukocytes also reside within the tumor microenvironment. In fact, various immune cells are 
capable of eliminating transformed cells and thus preventing tumorigenesis in a process 
termed immunosurveillance (Dunn et al., 2004). Whereas acute inflammation may prevent 
tumorigenesis by promoting an immune response directed against transformed cells, 
chronic inflammation promotes tumorigenesis. Rudolf Virchow is credited with making the 
seminal link between chronic inflammation and cancer by noting that human tumor 
biopsies were often infiltrated with inflammatory cells (Balkwill and Mantovani, 2001). 
Leukocytes can be detected in non-malignant tumors and carcinomas, including breast 
cancer (DeNardo and Coussens, 2007), which suggests an ongoing antitumor immune 
response. Despite the infiltration of leukocytes such as cytotoxic T-cells and NK-cells, the 
persistence of a tumor demonstrates immune evasion and highlights the local and systemic 
immune suppressive state of the tumor microenvironment and the tumor-bearing host, 
respectively. 
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4. Interleukin-6: A quintessential pleiotropic cytokine 
Interleukin-6 (IL-6) is an inflammation-associated cytokine and major inducer of C-reactive 
protein (CRP) throughout the acute phase inflammatory response. IL6 gene expression is 
nuclear factor-kappaB (NF-κB)-dependent (Chauhan et al., 1996) and produces a 26 kDa IL-6 
protein product. First characterized as a T-cell-derived factor that induced proliferation, 
differentiation, and immunoglobulin production in B-cells, IL-6 was originally named B-cell 
stimulating factor-2 (BSF-2). It was later thought to be a novel interferon (IFN-ǃ2) due to 
studies demonstrating the ability of IL-6 to activate signal transducer and activator of 
transcription 3 (STAT3) (Kishimoto, 2006). Complementary DNA encoding the human IL-6 
gene was subsequently cloned, and human IL-6 transgenic mice demonstrated a polyclonal 
IgG1 plasmacytosis phenotype (Suematsu et al., 1989). Next, IL-6 knockout (IL-6-/-) mice 
were generated and characterized. IL-6-/- mice underwent normal development, but adult 
animals exhibited reduced numbers of peripheral T-cells and impaired antiviral cytotoxic T-
cell activity (Kopf et al., 1994). In addition, IL-6 is a critical factor during hematopoiesis and 
subsequent lymphocyte differentiation and activation. Multiple diverse cell populations 
including fibroblasts, T and B-cells, monocytes, macrophages, endothelial cells, 
keratinocytes, astrocytes, and smooth muscle cells all have the potential to produce 
constitutive or inducible IL-6 (Kishimoto, 2006). 
Depending on cellular context, IL-6 can signal through multiple kinase-dependent 
proliferation and anti-apoptosis pathways including the mitogen-activated protein kinase 
(MAPK) pathway, the phosphatidylinositol-triphosphate kinase (PI-3K)/Akt pathway, and 
perhaps the most commonly evaluated in breast cancer, the Janus kinase (JAK)/signal 
transducer and activator of transcription-3 (STAT3) pathway (Hodge et al., 2005). To do so, a 
plasma membrane-associated IL-6 receptor (IL-6R/CD126) homodimer first ligates two 
soluble IL-6 molecules, which leads to gp130 (CD130) homodimer ligation. Whereas IL-6R is 
only expressed on hepatocytes, osteoclasts, and most immune cells under normal 
physiological conditions, gp130 is a ubiquitous and promiscuous receptor involved in 
multiple cytokine signaling pathways (e.g., IL-11, leukemia inhibitory factor (LIF), 
oncostatin M (OSM), and ciliary neurotrophic factor (CNTF)) (Rose-John et al., 2006). To 
initiate classical JAK/STAT3 signal transduction, JAK are recruited to the intracellular 
domain of the gp130 receptor where they bind and autophosphorylate. Subsequent gp130 
phosphorylation via activated JAK offers docking sites for STAT3 and other receptor-
associated proteins. Once bound to the intracellular domain of gp130, STAT3 is specifically 
phosphorylated (pSTAT3) by adjacent JAK on a C-terminal tyrosine residue (Y705), which 
grants its disengagement from the receptor. Dissociation of pSTAT3Y705 from gp130 
facilitates its homodimerization within the cytoplasm, and the pSTAT3Y705 homodimer 
translocates to the nucleus. There, pSTAT3Y705 binds to specific promoters whereby it 
initiates the transcription of multiple downstream target genes (Clevenger, 2004). Under 
normal physiological conditions, an inhibitory feedback loop maintains rapid and transient 
STAT3 activation. Following activation in normal cells, STAT3 induces suppressors of 
cytokine signaling (SOCS) and protein inhibitors of activated STATs (PIAS) expression. 
While SOCS-1 specifically inhibits JAK function, SOCS-3 binds the IL-6R complex to inhibit 
IL-6 signal transduction. PIAS-3 directly interacts with STAT3 to inhibit all STAT3 target 
gene expression (Kishimoto, 2006). In contrast, many human cancers, including breast 
cancer, exhibit constitutive STAT3 activity. Recent studies have demonstrated that 
unphosphorylated STAT3 (U-STAT3) accumulates in tumor cells with constitutively active 
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STAT3 where it forms a complex with NF-κB to activate a subset of NF-κB target genes 
(Yang and Stark, 2008). 
Alternatively, IL-6 trans-signaling describes an IL-6 signaling pathway whereby an IL-6 
soluble receptor (IL-6sR) binds IL-6 and subsequently ligates gp130 to stimulate STAT3 
activation in cells that only express gp130. IL-6sR is naturally produced by either proteolytic 
cleavage of the membrane-bound IL-6R or alternative splicing of IL-6R mRNA (Rose-John et 
al., 2006). Whereas IL-6 serum levels continue to increase with age, levels of serum IL-6sR 
rise until approximately age 70 at which time they gradually decline (Giuliani et al., 2001). 
Furthermore, IL-6sR expression has been demonstrated in human breast cancer cell lines 
(Crichton et al., 1996; Oh et al., 1996; Singh et al., 1995), suggesting that IL-6 trans-signaling 
mediates the effects of IL-6 in breast cancer cells. In contrast, an endogenous soluble gp130 
(sgp130) specifically antagonizes IL-6 trans-signaling by exclusively ligating the IL-6/IL-6sR 
complex, thus having no effect on cells that express the membrane-bound IL-6R (Rose-John 
et al., 2006) (Figure 1). 
 
 
Fig. 1. The IL-6/STAT3 signaling pathway 
5. Excessive IL-6 in human breast cancer 
Aberrantly elevated IL-6 is associated with a poor prognosis in breast cancer (Bachelot et al., 
2003; Salgado et al., 2003; Zhang and Adachi, 1999). Human breast tumors produce more IL-
6 when compared to matched healthy breast tissue, and tumor IL-6 levels concurrently 
increase with tumor grade. In addition, increased serum IL-6 has been demonstrated in 
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breast cancer patients compared to normal donors and correlates with advanced breast 
tumor stage (Kozlowski et al., 2003) and increased number of metastatic sites (Salgado et al., 
2003). Furthermore, a single nucleotide polymorphism (SNP) exists at position -174 in the 
IL-6 gene promoter region, noted as IL-6 (-174 G>C), with the following allele frequency in a 
Caucasion population:  36% G/G, 44% G/C, and 18% C/C. An inflammatory stimulus such 
as Salmonella typhii vaccination induced higher serum IL-6 in those individuals with the 
G/G allele (Bennermo et al., 2004). Although the IL-6 (-174 G>C) SNP is not associated with 
increased risk of developing breast cancer (Gonzalez-Zuloeta Ladd et al., 2006; Litovkin et 
al., 2007; Yu et al., 2009b), it is significantly associated with disease-free and overall survival 
in breast cancer patients (DeMichele et al., 2003). 
ERǂ is expressed in luminal subtype breast tumors (Perou et al., 2000) and therefore 
associated with improved patient survival (Buyse et al., 2006; Sorlie et al., 2001). A clear and 
well-characterized inverse correlation exists between breast cancer ERǂ status and IL-6. In 
fact, ERǂ directly binds to NF-κB, thus preventing transactivation of IL6 gene expression 
(Galien and Garcia, 1997), which demonstrates a direct mechanism for such a correlation. 
Furthermore, ERǂ-negative human breast tumors produce more IL-6 than tumors that 
express ERǂ (Chavey et al., 2007), and IL-6 serum levels are higher in ERǂ-negative breast 
cancer patients compared to ERǂ-positive patients (Jiang et al., 2000). Likewise, ERǂ-
negative breast cancer cell lines produce autocrine IL-6 whereas ERǂ-positive breast cancer 
cell lines do not (Sasser et al., 2007). Therefore, this strongly suggests that ERǂ-negative 
breast cancer cells would exploit both paracrine (i.e., stromal cell-derived) and autocrine IL-
6 signaling, whereas ERǂ-positive breast cancer cells could only utilize paracrine IL-6 
signaling. In addition, ERǂ-negative breast cancer patients, whose tumors produce more IL-
6 than those that express ERǂ (Chavey et al., 2007), showed no difference in survival 
between the G/G allele (higher inducible serum IL-6) and any C allele (lower inducible 
serum IL-6) at the IL-6 (-174 G>C) promoter SNP. In contrast, ERǂ-positive breast cancer 
patients with any C allele at the IL-6 (-174 G>C) promoter SNP demonstrated improved 
disease-free and overall survival compared to those with the G/G allele (DeMichele et al., 
2003). 
6. IL-6 promotes breast cancer cell growth 
Stromal fibroblasts isolated from multiple types of tumors (i.e., TAF) or cancers (i.e., CAF) 
are now appreciated as influential players in cancer progression and metastasis (Orimo and 
Weinberg, 2006). CAF derived from multiple cancer types, including murine mammary 
cancers, exhibit an activated, proinflammatory phenotype with increased IL-6 production 
(Erez et al., 2010). Furthermore, work from our laboratory has demonstated that fibroblasts 
isolated from breast tissue and common sites of breast cancer metastasis such as bone and 
lung enhance the growth of breast cancer cells in an IL-6-dependent manner, and IL-6 is the 
major fibroblast-derived soluble factor that induced STAT3 activation in breast cancer cells 
(Sasser et al., 2007; Studebaker et al., 2008). MDA-MB-231 breast cancer cells are commonly 
utilized to model triple negative breast cancer and produce autocrine IL-6. MDA-MB-231 
cells expressing a dominant negative isoform of gp130 lacked constitutively active STAT3 
and exhibited impaired tumorigenicity in an orthotopic xenograft model (Selander et al., 
2004), thus suggesting that IL-6 may drive tumor progression in this model. In addition, 
STAT3 is estimated to be constitutively activated in more than half of primary breast cancers 
due to IL-6 signaling (Berishaj et al., 2007). 
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Mesenchymal stem cells (MSC) are a bone marrow-derived fibroblast cell population that 
can be recruited to the breast tumor stroma, acquire a TAF phenotype, and produce high 
levels of IL-6. MSC enhance the growth of ERǂ-positive breast cancer cells, which do not 
express IL-6 or activated STAT3. In contrast, MSC have no effect on IL-6-producing ERǂ-
negative breast cancer cells, which express constitutively activated STAT3. Moreover, ERǂ-
positive breast cancer cells orthotopically co-injected with MSC or MSC conditioned 
medium and ERǂ-positive breast cancer cells that ectopically express IL-6 demonstrate 
enhanced xenograft tumor growth in the absence of exogenous 17ǃ-estradiol (Sasser et al., 
2007). Similar differential growth enhancement was demonstrated in vivo with ERǂ-positive 
and ERǂ-negative breast cancer cells co-injected with MSC, which also promoted metastasis 
(Karnoub et al., 2007). Interestingly, IL-6 has been reported to facilitate the recruitment of 
MSC to hypoxic breast tumor microenvironments (Rattigan et al., 2010). Likewise, IL-6 
secreted from breast cancer cells has been shown to contribute to a recently characterized 
phenomenon termed “self-seeding” in which aggressive circulating tumor cells engraft 
within their original xenograft tumor (Kim et al., 2009). MSC have also been shown to 
mediate the self-renewal capacity of breast cancer stem cells, in part, through a reciprocal IL-
6 loop (Liu et al., 2010). Taken together, preceding evidence strongly suggests that IL-6 
promotes breast cancer cell growth by activating STAT3, which culminates with the 
upregulation of proliferative oncogenes such as c-Myc and cyclin D1 and and growth factors 
such as IL-6, hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), 
and epidermal growth factor (EGF) (Yu et al., 2009a). 
7. IL-6 promotes epithelial-mesenchymal transition in breast cancer cells 
Normal polarized epithelial cells exhibit ‘cobblestone’ homophilic morphology and express 
E-cadherin, which is required for epithelial cell polarization, phenotype, and consequent 
homeostasis (Jeanes et al., 2008). E-cadherin is a key prognostic molecular biomarker 
clinically utilized to predict the metastatic propensity of breast cancer. Whereas very few 
studies have failed to demonstrate E-cadherin as an independent prognostic biomarker in 
breast cancer patients (Lipponen et al., 1994; Parker et al., 2001), the overwhelming majority 
of relevant studies have revealed E-cadherin as one of the strongest predictors of patient 
survival. Specifically, impaired E-cadherin expression in human breast tumors correlates 
with enhanced invasiveness, metastatic potential (Oka et al., 1993), and decreased breast 
cancer patient survival (Heimann and Hellman, 2000; Pedersen et al., 2002). While 
appropriate E-cadherin function is essential to the maintenance of epithelial cell 
morphology, phenotype, and homeostasis, regulation of E-cadherin expression is of equal 
importance. CDH1, the gene that encodes E-cadherin, is located on human chromosome 
16q22.1 (Rakha et al., 2006) and is susceptible to inactivation by promoter hypermethylation, 
somatic mutation, or aberrant overexpression of repressive transcription factors including 
Twist, Snail, and Slug among others (Hirohashi, 1998). Likewise, E-cadherin loss of function 
can arise due to extracellular domain-specific proteolytic cleavage. Although uncommon, 
germline mutations of CDH1 predispose individuals to hereditary diffuse gastric cancer 
(HDGC) syndrome, and a proportion of these patients present with other cancers, including 
breast cancer (Guilford, 1999). 
E-cadherin was initially termed uvomorulin in mice and L-CAM in chicks following its 
discovery as a 120 kDa calcium-dependent trypsin-labile cell surface glycoprotein required 
for intercellular adhesion in mouse blastomeres (Hyafil et al., 1981) and chick embryos 
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(Brackenbury et al., 1981). It now represents the best studied member of the cadherin family 
of tissue-specific homophilic intercellular adhesion molecules. E-cadherin knockout studies 
have demonstrated early embryonic lethality due to impaired maintenance of epithelial 
polarity and failure to form an intact epithelium in E-cadherin-/- embryos (Larue et al., 1994). 
E-cadherin is localized on the cell surface of epithelial cells, and each E-cadherin protein 
consists of an amino-terminal extracellular domain, a single-pass transmembrane segment, 
and a carboxy-terminal intracellular domain. Five calcium-binding repeated subunits 
comprise an extracellular domain that promotes homophilic interaction to ultimately form 
anti-parallel trans-E-cadherin dimers between adjacent cells (Guilford, 1999). The 
intracellular domain is comprised of a juxtamembrane p120-catenin binding subdomain and 
a C-terminal beta (ǃ)-catenin binding subdomain. ǃ-catenin, a potent transcription factor, 
binds E-cadherin and alpha (ǂ)-catenin subsequently binds ǃ-catenin. Although contentious 
(Weis and Nelson, 2006), it is generally acknowledged that ǂ-catenin interacts with F-actin 
and thereby, facilitates the linkage of E-cadherin to the cytoskeleton. This E-cadherin-
catenin-actin complex localizes to epithelial intercellular junctions called adherens junctions 
and is critical to epithelial cell adhesion, polarity, and morphology (Hartsock and Nelson, 
2008). Furthermore, E-cadherin sequesters ǃ-catenin at the cell surface as one means to 
inhibit ǃ-catenin nuclear translocation and consequent expression of ǃ-catenin responsive 
genes (Perez-Moreno et al., 2003). 
Another prominent role of E-cadherin is that of an invasion/metastasis suppressor 
protein. Upon loss of E-cadherin and subsequent dissociation of adherens junctions, 
epithelial cells acquire enhanced invasive capability (Behrens et al., 1989). MDA-MB-231 
cells, an ERǂ-negative breast cancer cell line, lack E-cadherin, whereas MCF-7 cells, an 
ERǂ-positive breast cancer cell line express high levels of E-cadherin (Kenny et al., 2007), 
and MDA-MB-231 cells exhibit enhanced invasive capability compared to MCF-7 cells 
(Sommers et al., 1991). Naturally, E-cadherin expression and consequent invasive capacity 
regulate the propensity of breast cancer metastasis. Multiple signaling pathways are 
activated following loss of E-cadherin protein, which promote transformed human breast 
epithelial cell metastasis in a xenograft model. Interestingly, Twist, a transcriptional 
repressor of CDH1, is induced upon loss of E-cadherin and is necessary for metastasis in 
this model. Furthermore, the E-cadherin binding partner, ǃ-catenin, was shown to be 
necessary but not sufficient for the EMT phenotype induced following loss of E-cadherin 
(Onder et al., 2008). Ectopic expression of murine E-cadherin in highly metastatic human 
MDA-MB-231 cells significantly reduced osteolytic bone metastases in a murine 
intracardiac dissemination model (Mbalaviele et al., 1996). Likewise, aberrant cytoplasmic 
or diminished to negative E-cadherin immunostaining patterns are commonly detected in 
invasive poorly differentiated breast carcinomas compared to noninvasive well-
differentiated breast carcinomas and are associated with increased probability of breast 
carcinoma metastasis (Oka et al., 1993). The finding that distant metastases often express 
E-cadherin even in patients which exhibit primary breast carinomas which lack E-
cadherin suggests that ultimate re-expression may be necessary for colonization of 
secondary tissues (Kowalski et al., 2003; Saha et al., 2007). 
Loss of E-cadherin is a prerequisite for epithelial-mesenchymal transition (EMT), a highly 
conserved process which exemplifies the aberrant activation of an embryonic gene 
expression program during carcinoma progression. EMT is critical for multiple steps of 
developmental metazoan cellular morphogenesis as demonstrated in well-characterized 
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Drosophila and Xenopus models. Throughout embryonic development, EMT whereby 
epithelial cells give rise to more motile mesenchymal cells is essential for mesoderm and 
neural crest formation. Importantly, this is a transient process and mesenchymal-epithelial 
transition (MET) allows for cellular reversion (Yang and Weinberg, 2008). 
Whereas EMT has been extensively studied for its essential role in embryogenesis, the 
concept of EMT-like cellular changes in human cancers has gained acceptance as a major 
mechanism to promote primary tumor cell invasion and subsequent tumor metastasis. A 
carcinoma cell must first detach from the primary tumor and invade through the basement 
membrane into the underlying tissue parenchyma to initiate the metastasic cascade. 
Although cancer-associated EMT was considered a controversial notion even in recent years 
(Tarin et al., 2005), it has been demonstrated in multiple human carcinomas, including breast 
cancer (Cheng et al., 2008; Heimann and Hellman, 2000; Moody et al., 2005; Sarrio et al., 
2008), and is now recongnized as a putative mediator of tumor metastasis. An EMT 
phenotype including impaired E-cadherin expression with concominant induction of 
Vimentin, Alpha-smooth-muscle-actin, and/or N-cadherin is associated with the basal 
breast cancer subtype, suggesting that EMT may promote characteristic aggressiveness in 
these tumors and contribute to poor breast cancer patient survival (Sarrio et al., 2008). 
Likewise, relatively noninvasive ERǂ-positive MCF-7 cells express E-cadherin, consistent 
with a characteristic epithelial phenotype, and are classified as luminal subtype, whereas 
highly invasive ERǂ-negative MDA-MB-231 cells lack E-cadherin and are classified as basal 
subtype (Blick et al., 2008). Furthermore, ERǂ directly correlates with E-cadherin in primary 
human breast tumors (Ye et al., 2010). While EMT may enhance carcinoma cell invasion and 
subsequent dissemination which would increase metastatic potential, it is not synonymous 
with metastasis in all models. For example, Lou, et al. demonstrated that EMT alone was 
insufficient for spontaneous murine mammary carcinoma metastasis (Lou et al., 2008). Yet, 
Weinberg and colleagues described the promotion of metastasis with loss of E-cadherin and 
a consequent EMT phenotype in transformed human breast epithelial cells (Onder et al., 
2008). 
Our laboratory has previously demonstrated that exogenous IL-6 exposure induced an EMT 
phenotype in a panel of human ERǂ-positive breast cancer cells, which included E-cadherin 
repression and concomitant induction of Vimentin, N-cadherin, Snail, and Twist. In 
addition, ectopic expression of IL-6 in ERǂ-positive MCF-7 breast cancer cells promoted an 
EMT phenotype and enhanced invasiveness. Likewise, MCF-7 cells with ectopic Twist 
expression exhibit an EMT phenotype (Mironchik et al., 2005), autocrine IL-6 production, 
and constitutive STAT3 activation (Sullivan et al., 2009). 
8. Therapeutic targeting of the IL-6/STAT3 pathway 
IL-6 levels are increased in human breast tumors and breast cancer patient sera, and 
excessive IL-6, both circulating and within the breast tumor microenvironment, is associated 
with poor clinical outcomes in breast cancer. STAT3, a critical downstream mediator of IL-6 
signaling, is constitutively activated in more than half of human cancers and promotes the 
expression of proliferative, anti-apoptotic, immune suppressive, and pro-angiogenic target 
genes, which all potentiate carcinogenesis. Whereas the IL-6 signaling network has been 
targeted in numerous autoimmune diseases and cancers, this therapeutic strategy has yet to 
be clinically employed for breast cancer. Increased preclinical reports have revealed novel 
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mechanisms underlying IL-6/STAT3 signaling in breast cancer cells such as enhanced 
growth, induction of EMT, multidrug resistance, and recruitment of peripheral fibroblasts. 
Taken together, accumulating preclinical and clinical data emphasize IL-6 as a highly 
attractive therapeutic target in breast cancer. It is therefore imperative that more work be 
done to evaluate current therapeutics and develop novel agents that target IL-6/STAT3 
signaling in breast cancer models. 
Multiple strategies could be utilized to target the IL-6/STAT3 pathway, but first and most 
obvious would be anti-IL-6 neutralizing antibodies. One such anti-IL-6 monoclonal 
antibody is Siltuximab (CNTO 328). The safety and efficacy of Situximab has been 
demonstrated in preclinical studies and phase I/II clinical trials of diverse human 
pathologies and malignancies including Castleman’s disease (van Rhee et al., 2010), 
multiple myeloma (Hunsucker et al., 2011; Voorhees et al., 2007), prostate cancer 
(Cavarretta et al., 2007; Cavarretta et al., 2008; Dorff et al., 2010; Karkera et al., 2011), renal 
cell carcinoma (Puchalski et al., 2010; Rossi et al., 2010), non-small cell lung cancer (Song et 
al., 2010), and ovarian cancer (Guo et al., 2010). Furthermore, IL-6R can be targeted with 
tocilizumab, an anti-IL-6R monoclonal antibody that has shown promising results in IL-6-
driven autoimmune diseases (Tanaka et al., 2011) and was recently approved by the FDA 
for the treatment of rheumatoid arthritis. The promiscuous IL-6 coreceptor, gp130, also 
has an endogenous soluble form (sgp130) that exclusively inhibits IL-6 trans-signaling, 
thus preserving classical IL-6 signaling. Therapeutic sgp130 would potentially be more 
targeted toward breast cancer cells, which generally lack membrane-associated IL-6R and 
therefore utilize IL-6 trans-signaling through IL-6sR. Recombinant soluble gp130 (sgp130-
Fc) has been shown to inhibit murine colon carcinogenesis (Becker et al., 2004), suggesting 
that it may prove effective in breast cancer as well. Finally, a growing number of non-
selective kinase inhibitors and recent focus on specific JAK and STAT3 inhibitor 
development will provide further insight into the roles of JAK and STAT3 in breast 
cancer. 
9. Conclusions 
Breast cancer is a heterogeneous disease and thus, highly variable across individual patients. 
This heterogenicity arises not only due to the diversity of genetic and molecular aberrations 
in primary breast cancer cells but also due to the diversity of cellular populations that 
inhabit the breast tumor microenvironment. Although IL-6 levels are higher in breast 
tumors and patient sera, the precise source of this IL-6 remains elusive. Importantly, many 
breast tumor stromal cells provide a paracrine source of IL-6 for breast cancer cells within 
the breast tumor microenvironment. In addition, certain clinical subtypes of breast cancers 
and research models, such as ERǂ-negative primary breast cancers and ERǂ-negative breast 
cancer cell lines, produce excessive IL-6 (Figure 2). Therefore, ERǂ-negative breast cancer 
cells may supply the tumor microenvironment with IL-6 by means of autocrine IL-6 
production to exacerbate the poor prognosis associated with this clinical subtype. It will be 
critical to determine the specific cellular source of breast tumor-associated IL-6 to advance 
our understanding of this pleiotropic cytokine in breast cancer progression and metastasis. 
Moreover, this knowledge will facilitate the validation and subsequent clinical utility of 
current and novel targeted antagonists of the IL-6/STAT3 signaling network in breast 
cancer. 
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Fig. 2. Breast cancer cell ERǂ status dictates paracrine vs. autocrine IL-6 utilization. 
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